Xtant Medical Holdings, Inc. revised earnings guidance for the year 2023. For the year, the company raises its expectation for full year 2023 revenue to $88 million to $91 million, up from the Company?s prior guidance of $75 million to $77 million. The revised guidance range represents annual revenue growth of approximately 52% to 57% compared to full year 2022 revenue, and includes contributions from the Surgalign transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.791 USD | -3.22% | -3.49% | -30.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.00% | 106M | |
+10.86% | 124B | |
-5.42% | 11.17B | |
+4.17% | 9.17B | |
-21.47% | 4.71B | |
+8.77% | 3.44B | |
-6.03% | 2.88B | |
-12.05% | 2.11B | |
-7.83% | 2.09B | |
-22.84% | 1.8B |
- Stock Market
- Equities
- XTNT Stock
- News Xtant Medical Holdings, Inc.
- Xtant Medical Holdings, Inc. Revises Earnings Guidance for the Year 2023